Read more

April 03, 2023
2 min watch
Save

VIDEO: Unresolved debates on myopia progression strategies create confusion

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Key takeaways:

  • Myopia progression can be slowed down.
  • Lack of consensus on the best strategies creates confusion.

VILAMOURA, Portugal — At the ESCRS winter meeting, Paolo Nucci, MD, addressed the hot topic of myopia control. Myopia progression can be slowed down, he said, but consensus on treatment options and optimization has not been reached.

“Atropine at low concentration is available, but scientists are debating if 0.01%, 0.02% or 0.05% is the best option, and this creates confusion,” he said. “Defocus lenses have been studied for almost 20 years. Now we have different types of defocus lenses, but competition among the industries also creates confusion.”

He also expressed skepticism about options that are not evidence based, such as repeated low-level red-light therapy.